News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Big Pharma Share Buybacks Not Impacting R&D Budgets



7/18/2017 6:13:16 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
In her Sunday business column in the New York Times, Gretchen Morgenson went after Big Pharma and the propensity for companies to buy back shares of their own stocks. Entitled “When Big Pharma Spends, Research Isn’t No. 1”, Morgenson focuses on an academic study that concludes that “from 2006 through 2015, the 18 drug companies in the Standard & Poor’s 500 index spent a combined $526 billion on buybacks and dividends” - an amount that exceeded by 11% the companies’ R&D spending of $465 billion during these years.

Read at Forbes


comments powered by Disqus
Forbes
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES